The federal government is stepping back from a deliberate, two-year effort to keep Medicare Part D premiums from swinging under the redesigned drug benefit. The Centers for Medicare & Medicaid Services confirmed on July 28 that it will end the Part D Premium Stabilization Demonstration at the close of calendar year 2026, returning standalone drug-plan pricing to ordinary market conditions for 2027. The agency’s own bid data already shows the effect: the national base beneficiary premium, the statutory figure used to set plan pricing and penalties alike, rises to $41.33 from $38.99. For retirees who pay a standalone Part D premium separate from the rest of what their Medicare card covers, the removal of that government backstop, not the dollar amount by itself, is the actual story.
The Subsidy Behind Two Years of Calmer Bids
CMS built the demonstration in 2025 specifically because the Inflation Reduction Act’s redesign of Part D, which capped enrollee out-of-pocket spending and shifted more reinsurance risk onto insurers, introduced enough pricing uncertainty that some standalone plan bids swung sharply from one contract year to the next. The voluntary program let CMS smooth the year-over-year bid growth insurers could build into their pricing, a cushion meant to keep enrollees from absorbing the full cost of insurers’ early guesswork about the newly redesigned benefit.
The agency’s stated reason for ending the demonstration now is that plan sponsors have accumulated enough real claims experience under the redesigned benefit to price 2027 bids without that cushion, so CMS says it will return the program to operating under traditional market conditions in CY 2027. That reasoning matters more than the $41.33 figure by itself, because the base beneficiary premium is a statutory calculation used to set the starting point for plan pricing and penalties, not the sticker price any single enrollee will see once a specific standalone plan publishes its 2027 premium.
Free download: What to ask the plan, the prescriber and the pharmacy, when to request an exception, and which records to keep. Download the free prescription coverage checklist.
The Deductible and Coverage Gap Move at the Same Time
The premium is not the only 2027 figure moving. Medicare’s published guidance sets the maximum allowable Part D deductible at $700 in 2027, up from $615 in 2026, an $85 increase in how much a beneficiary can be required to pay before a plan’s cost-sharing begins. No Part D plan may set a deductible above that ceiling, though many plans set lower deductibles or waive them for certain drug tiers.
The threshold for reaching catastrophic coverage, the stage at which a Part D enrollee stops paying anything further for covered drugs for the rest of the calendar year, is rising in the same direction, to $2,400 in 2027 from $2,100 in 2026. Both figures come from the same annual recalculation process CMS uses to implement the Inflation Reduction Act’s redesigned benefit, and both move independently of the base beneficiary premium even though every change takes effect in the identical plan year.
Layered together, the changes compound rather than offset one another: a beneficiary now needs $85 more in drug spending before cost-sharing even begins, then $300 more in total out-of-pocket costs before free catastrophic coverage takes over, while also paying a higher monthly premium simply to stay enrolled. Nothing in the 2027 bid data trades a higher premium for an earlier catastrophic threshold or a lower deductible; all three figures move in the same direction in the same plan year.
The Late-Enrollment Penalty Rides on the Same Number
The base beneficiary premium does more than anchor plan bids. It is also the exact figure Medicare multiplies to calculate the Part D late-enrollment penalty for anyone who went 63 days or more without creditable drug coverage after their initial enrollment period ended. The penalty formula adds 1% of the national base beneficiary premium for every full month of that gap, permanently, to a beneficiary’s monthly premium for as long as they carry Medicare drug coverage.
That structure means the group most exposed to the 2027 change is not new enrollees weighing plans during open enrollment, but people already carrying a penalty from a coverage gap years earlier. Using the 2026 base premium, a 14-month gap produces a $5.50 monthly penalty; applying the same 14% rate to the 2027 base premium raises that same long-standing penalty again, without the beneficiary having changed anything. The dollar increase is small in isolation, but it recurs on top of a premium that is also rising, and it applies for as long as the person keeps Medicare drug coverage rather than resetting.
What CMS Still Has to Confirm This Month
CMS has said it will release final 2027 Medicare Advantage and Part D premiums, along with the complete plan landscape, in mid-to-late September, once insurers finalize their offerings. Until that release, the $41.33 base beneficiary premium and the $296.05 national average monthly bid amount describe the inputs behind 2027 pricing, not the premium any specific standalone plan will actually charge; some plans price well above the base premium, others closer to it, and no single plan’s exact 2027 premium is public until the landscape file appears ahead of open enrollment.
What is settled, according to CMS’s own fact sheet, is that the temporary buffer between the redesigned benefit and full market pricing is gone, and the agency says plainly it made that choice because plan sponsors had enough experience to price the risk on their own. Whether standalone plan sponsors treat the subsidy’s end as room to raise premiums beyond the base figure, or hold pricing close to it heading into a competitive open enrollment, is a question the bid data cannot answer; only the landscape file CMS has promised for September will show it.
Absorbing a Drug-Plan Premium Increase
None of the CMS figures above show what a specific standalone plan will actually charge once its 2027 premium, deductible and formulary are finalized, or which state-level cost-help programs might offset part of that increase before the first 2027 premium bill arrives. The bid data explains why the base premium moved; it does not walk through the prior-authorization appeal steps or cost-tracking a beneficiary needs once a plan’s actual 2027 pricing is public.
The Medicare Cost & Coverage Protection Kit is a 10-page kit built around 51 state Medicare cost-help packs, the new Part D out-of-pocket cap and the prior-authorization appeal steps beneficiaries can use once a plan’s 2027 pricing takes effect.
See the state cost-help packs and appeal steps in The Medicare Cost & Coverage Protection Kit.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
